Bharat Biotech's intranasal vaccine to enter phase I/II trials by month-end

Vaccine producer Bharat Biotech International (BBIL) could begin phase I/II human clinical trials for its single-dose intranasal vaccine candidate for Covid-19 by the end of December or early next month, its chairman, Krishna Ella, said on Tuesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2K2AY4a
via IFTTT